CertiK Partners with Alibaba Cloud to Bring Blockchain Security to the Cloud
New York, May 15, 2023 (GLOBE NEWSWIRE) -- CertiK, the New York-based blockchain security company, and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, announced the signing of a partnership to provide blockchain security services to cloud-based Web3 projects. Web3 developers can now accelerate their development process and secure their applications and smart contracts with CertiK’s Security Suite and Alibaba Cloud’s scalable, highly efficient, and secure infrastructure.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
Cloud-based computing services have driven the evolution of communications technology over the last decade, and cybersecurity has played a key role. New technology is not suitable for mass adoption until it has proven itself to be secure, which is exactly what CertiK is bringing to Alibaba Cloud’s Blockchain as a Service (BaaS) platform.
Blockchain is a novel technology that unlocks powerful new ways to perform secure, decentralized, and highly-efficient distributed computing. The integration of Web3 applications, smart contracts, and blockchains is the next step in the evolution of cloud computing.
With this new partnership, developers and enterprises can conduct code reviews, risk assessments, team identity verification, background checks, and more using the services and tools provided by CertiK and deployed on Alibaba Cloud.
Alibaba Cloud has gone live with CertiK's smart contract auditing service and Layer 1 blockchain auditing service fully integrated. In the near future, penetration testing and CertiK's Skynet due diligence tool will also be introduced, providing end-to-end security solutions.
“We’re excited to bring our years of blockchain security experience to Alibaba Cloud’s platform,” said CertiK co-founder, Prof. Ronghui Gu. “We’ve believed in the power of blockchain technology for over half a decade, and to see Alibaba Cloud commit to this same vision and embrace a comprehensive approach to security is extremely rewarding. We look forward to bringing secure blockchain development and deployment to the widest audience possible.”
"Alibaba Cloud has always been committed to providing customers with safe and reliable cloud computing services, and actively promoting the development of new technologies and applications. This cooperation will provide us with more comprehensive technical support and security solutions to better serve the blockchain and Web3 ecosystem,” said Raymond Xiao, Head of International Web3 Solutions, Alibaba Cloud Intelligence
CertiK experts will monitor deployments to Alibaba Cloud environments, helping developers and enterprises perform secure cloud computing, maintain high-uptime cloud storage, and build secure infrastructure, while automated tools run behind the scenes and around the clock.
In addition, the upcoming Skynet vulnerability scanning platform scans code and identifies vulnerabilities in real time, providing developers with real-time monitoring and remediation recommendations.
Beyond the integration of the Security Suite, CertiK and Alibaba Cloud will support the continued growth of the Web3 world through the joint organization of hackathons, developer education sessions, and application development programs.
About CertiK
CertiK is a pioneer in blockchain security, leveraging best-in-class AI technology and expert manual review to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK secures the Web3 world, by applying cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness. CertiK has audited more than 3,900 Web3 projects and secured hundreds of billions of dollars of market capitalization.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone11.12.2023 01:30:59 CET | Press release
Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapyResults shared during oral presentation at ASH 2023 plenary scientific session PARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidatio
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)11.12.2023 01:30:00 CET | Press release
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority of patients, with a safety profile consistent with previously reported data1-5 Patients switching from anti-C5s to Fabhalta in the extension period achieved outcomes comparable to the Fabhalta arm in the 24-week randomized controlled period, including transfusion avoidance and near-normal hemoglobin-levels (≥12 g/dL) in the majority of patients1 Fabhalta was recently approved by the FDA for adults with PNH, including for both previously treated and treatment-naive patients6 Basel, December 11, 2023 – Novartis today announced results from the extension period of the pivotal Phase III APPLY-PNH trial of oral monotherapy Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) who h
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia10.12.2023 18:05:00 CET | Press release
Part 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC:Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic events or treatment-related sustained elevations of D-dimer observedPoster presentation at American Society of Hematology (ASH) Annual meeting Registrational PRESent-2 and PRESent-3 studies of SerpinPC in hemophilia B are ongoing BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated protein C (APC) in registrational studies for the treatment for hemoph
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo